Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's Victrelis is still likely to have a marketing advantage of one to two months over J&J's Incivek in the EU hepatitis C market, but pricing and reimbursement issues in the Member States will probably drive market share more than anything else.

You may also be interested in...



Merck Victrelis Glowing Recommendation From NICE At Odds With IQWiG

The contrasting views in Germany and England for the hepatitis C product underscore the difference between IQWiG’s purely scientific assessment and NICE’s focus on cost-effectiveness.

Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results

Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.

Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results

Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel